Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.

作者: S. Kroesen

DOI: 10.1093/RHEUMATOLOGY/KEG263

关键词: Rheumatoid arthritisArthritisSurgeryDiseaseInfliximabInfectious disease (medical specialty)Internal medicineMedicineTuberculosisEtanerceptPlacebo

摘要: Objective. With rising numbers of anti-tumour necrosis factor a (TNF-a) treatments for rheumatoid arthritis (RA), Crohn’s disease and other conditions, physicians unaware potential pitfalls are increasingly likely to encounter associated severe infections. Our purpose was assess the incidence nature infections in our RA patients under anti-TNF-a therapy. Methods. We reviewed patient charts records Infectious Disease Unit serious with 2 yr preceding therapy during Results. Serious affected 18.3% treated infliximab or etanercept. The 0.181 per treatment year vs 0.008 In several cases, only few signs symptoms indicated severity developing infections, including sepsis. Conclusions. A high level suspicion infection is necessary suggest additional strategies prevention, rapid identification pre-emptive such efficacy (TNFa) agents etanercept (RA) has been demonstrated large-scale trials w1‐4x. Their results indicate superior effect these compared conventional disease-modifying anti-rheumatic drugs (DMARDs). Among undesired effects agents, have primary concern. Under study 53% group 3m gukg together methotrexate had an 40% placebo w1x. For any given infection, difference between groups statistically significant. However, defined as life-threatening requiring hospitalization, not different over dose ranges studied (6% 1% every 8 weeks 6% 10 mg 4 weeks). etanercept, occurred 51% active 63% w3x. On basis data, it assumed that were markedly increased when data on w5‐7x. Recently, reactivation tuberculosis, again raising concerns may pose significant threat w8x. addition existing warnings contained package insert, case latter FDA (Food Drug Administration, USA) requested ‘black box’ recommendations concerning tuberculosis. So far, postmarketing surveys revealed problems because course infectious be altered by therapy, critical importance consider this aspect care patients. evaluated series from institution which highlight difficulties

参考文章(14)
Ravinder Maini, E William St Clair, Ferdinand Breedveld, Daniel Furst, Joachim Kalden, Michael Weisman, Josef Smolen, Paul Emery, Gregory Harriman, Marc Feldmann, Peter Lipsky, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial The Lancet. ,vol. 354, pp. 1932- 1939 ,(1999) , 10.1016/S0140-6736(99)05246-0
PIER PAOLO MARIANI, FABRIZIO MARGHERITINI, Septic Arthritis of the Knee Techniques in Knee Surgery. ,vol. 2, pp. 117- 124 ,(2003) , 10.1097/00132588-200306000-00007
Joseph Keane, Sharon Gershon, Robert P. Wise, Elizabeth Mirabile-Levens, John Kasznica, William D. Schwieterman, Jeffrey N. Siegel, M. Miles Braun, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent The New England Journal of Medicine. ,vol. 345, pp. 1098- 1104 ,(2001) , 10.1056/NEJMOA011110
Per Riegels-Nielsen, Jørgen Steen Jensen, Septic arthritis of the knee. Five cases treated with synovectomy. Acta Orthopaedica Scandinavica. ,vol. 55, pp. 657- 659 ,(1984) , 10.3109/17453678408992417
Jose G. Castro, Lorraine Dowdy, Septic Shock Caused by Staphylococcus lugdunensis Clinical Infectious Diseases. ,vol. 28, pp. 681- 682 ,(1999) , 10.1086/517215
Michele F. Doran, Cynthia S. Crowson, Gregory R. Pond, W. Michael O'Fallon, Sherine E. Gabriel, Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis & Rheumatism. ,vol. 46, pp. 2287- 2293 ,(2002) , 10.1002/ART.10524
B. E. E. M. van den Borne, R. B. M. Landew�, I. Houkes, F. Schild, P. C. W. van der Heyden, J. M. W. Hazes, J. P. Vandenbroucke, A. H. Zwinderman, H. S. Goei The, F. C. Breedveld, H. J. Bernelot Moens, P. M. Kluin, B. A. C. Dijkmans, No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis & Rheumatism. ,vol. 41, pp. 1930- 1937 ,(1998) , 10.1002/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N
Larry W. Moreland, Etanercept Therapy in Rheumatoid Arthritis Annals of Internal Medicine. ,vol. 130, pp. 478- 486 ,(1999) , 10.7326/0003-4819-130-6-199903160-00004
R. N. Maini, P. C. Taylor, Anti-cytokine therapy for rheumatoid arthritis. Annual Review of Medicine. ,vol. 51, pp. 207- 229 ,(2000) , 10.1146/ANNUREV.MED.51.1.207
P. PRIOR, D. P. M. SYMMONS, D. L. SCOTT, R. BROWN, C.F. HAWKINS, CAUSE OF DEATH IN RHEUMATOID ARTHRITIS Rheumatology. ,vol. 23, pp. 92- 99 ,(1984) , 10.1093/RHEUMATOLOGY/23.2.92